Literature DB >> 34643244

The Importance of Assessing Burning and Stinging when Managing Rosacea: A Review.

Martin Schaller1, Thomas Dirschka, Sol-Britt Lonne-Rahm, Giuseppe Micali, Linda F Stein Gold, Jerry Tan, James Del Rosso.   

Abstract

Rosacea, a chronic condition usually recognized by its visible presentation, can be accompanied by invisible symptoms, such as burning and stinging. The aim of this review is to gather the most recent evidence on burning and stinging, in order to further emphasize the need to address these symptoms. Inflammatory pathways can explain both the signs and symptoms of rosacea, but available treatments are still evaluated primarily on their ability to treat visible signs. Recent evidence also highlights the adverse impact of symptoms, particularly burning and stinging, on quality of life. Despite an increasing understanding of symptoms and their impact, the management of burning and stinging as part of rosacea treatment has not been widely investigated. Clinicians often underestimate the impact of these symptoms and do not routinely include them as part of management. Available therapies for rosacea have the potential to treat beyond signs, and improve burning and stinging symptoms in parallel. Further investigation is needed to better understand these benefits and to optimize the management of rosacea.

Entities:  

Mesh:

Year:  2021        PMID: 34643244      PMCID: PMC9425614          DOI: 10.2340/actadv.v101.356

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  56 in total

Review 1.  Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skin.

Authors:  James Q Del Rosso; Richard L Gallo; Leon Kircik; Diane Thiboutot; Hilary E Baldwin; David Cohen
Journal:  J Drugs Dermatol       Date:  2012-06       Impact factor: 2.114

2.  Defining treatment success in rosacea as 'clear' may provide multiple patient benefits: results of a pooled analysis.

Authors:  Guy Webster; Martin Schaller; Jerry Tan; J Mark Jackson; Nabil Kerrouche; Gregor Schäfer
Journal:  J Dermatolog Treat       Date:  2017-07-04       Impact factor: 3.359

Review 3.  Sensitive skin: an overview.

Authors:  E Berardesca; M Farage; H Maibach
Journal:  Int J Cosmet Sci       Date:  2012-09-21       Impact factor: 2.970

4.  Successful therapy of ocular rosacea with topical ivermectin.

Authors:  M Schaller; K Pietschke
Journal:  Br J Dermatol       Date:  2018-05-30       Impact factor: 9.302

Review 5.  Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2017-09-01

6.  Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel.

Authors:  M Schaller; L M C Almeida; A Bewley; B Cribier; N C Dlova; G Kautz; M Mannis; H H Oon; M Rajagopalan; M Steinhoff; D Thiboutot; P Troielli; G Webster; Y Wu; E van Zuuren; J Tan
Journal:  Br J Dermatol       Date:  2017-02-05       Impact factor: 9.302

7.  Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study.

Authors:  Todd Williamson; Wendy Y Cheng; Nora McCormick; Francis Vekeman
Journal:  Am Health Drug Benefits       Date:  2018-04

8.  Chitin modulates innate immune responses of keratinocytes.

Authors:  Barbara Koller; Alisa Sophie Müller-Wiefel; Rudolph Rupec; Hans Christian Korting; Thomas Ruzicka
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

Review 9.  Recent advances in the understanding and management of rosacea.

Authors:  Uwe Wollina
Journal:  F1000Prime Rep       Date:  2014-07-08

10.  Fluorescent light energy: Treating rosacea subtypes 1, 2, and 3.

Authors:  Mario Sannino; Giuseppe Lodi; Markus Wied Dethlefsen; Steven Paul Nisticò; Giovanni Cannarozzo; Michael Canova Engelbrecht Nielsen
Journal:  Clin Case Rep       Date:  2018-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.